Know Cancer

or
forgot password

Open Label, Randomized, Multicentric, Comparative and Controlled Clinical Trial to Compare the Efficacy and Toxicity of Mycobacterium w Intra-dermal to Intravesical BCG in Patients With Newly Diagnosed Superficial Transitional Cell Carcinoma With High Probability of Recurrence


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Bladder Cancer

Thank you

Trial Information

Open Label, Randomized, Multicentric, Comparative and Controlled Clinical Trial to Compare the Efficacy and Toxicity of Mycobacterium w Intra-dermal to Intravesical BCG in Patients With Newly Diagnosed Superficial Transitional Cell Carcinoma With High Probability of Recurrence


Inclusion Criteria:



- Ability to understand and willingness to sign a written informed consent.

- Patients with newly diagnosed superficial transitional cell carcinoma with completely
resected papillary tumors and high probability of recurrence risk i.e. stage T1 Grade
2, T1 Grade 3 & CIS.

and Ta or T1 disease with an increased risk of recurrence defined as 2 tumors (primary and
recurrent or 2 recurrences) within 1 year, 3 or more within the last 6 months and/ or
carcinoma in situ on at least one random biopsy.

- 18 years or above

- ECOG of 0-2 range

- life expectancy is at least 24 weeks.

- Absolute neutrophil count≥1,500/c.mm

- platelet count≥100,000//c.mm

- Hemoglobin ≥9.0g/dL

- No patient who has eczema will be allowed to participate in this study.

- Patients who are immuno-compromised will not be enrolled.

- Patients with severe hepatic dysfunctions or with evidence of Cirrhosis will not
be enrolled.

- Patients with uncontrolled diabetes mellitus will not be enrolled in the study

- No evidence of residual tumor in the cystoscopy done 6 weeks after the TUR

Note: The effects of Investigational product on the developing human fetus is at the
recommended therapeutic dose are unknown. For this reason and because other therapeutic
agents used in this trial are known to be teratogenic, women of child bearing potential
and men must agree to use adequate contraception (hormonal or barrier method of birth
control; abstinence) prior to study entry and for the duration of study participation.
Should a woman become pregnant or suspect she is pregnant while participating in this
study, she should inform her treating physician immediately.

Exclusion Criteria:

- Patients who have had cytotoxic chemotherapy or radiotherapy prior to entering the
study.

- No patient who has eczema should be allowed to participate in this study.

- Patients who are immuno-compromised should not be enrolled.

- Patients with severe hepatic dysfunctions or evidence of Cirrhosis should not be
enrolled.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to agents used in the study.

- Pregnant women or nursing women are excluded from this study because agents used in
the study have potential for teratogenic or abortifacient effects. Because there is
known potential risk for adverse events in nursing infants secondary to treatment of
the mother with investigational agent, breastfeeding should be discontinued if the
mother is treated with investigational product.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Hypersensitivity to celecoxib, sulfonamides, aspirin, other NSAIDs, or any study
reagent

- Previous splenectomy

- Clinically significant active infection

- Patients with uncontrolled diabetes mellitus.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Recording of any clinical adverse reactions at anytime during the study for assessment of safety

Outcome Time Frame:

24 months

Safety Issue:

Yes

Principal Investigator

Mahesh Desai, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Muljibhai Patel Urological Hospital

Authority:

India: Drugs Controller General of India

Study ID:

CR-60/9150

NCT ID:

NCT00694915

Start Date:

August 2008

Completion Date:

February 2014

Related Keywords:

  • Bladder Cancer
  • STCC (Superficial Transitional Cell Carcinoma)
  • Urinary Bladder Neoplasms
  • Carcinoma
  • Carcinoma, Transitional Cell
  • Mycobacterium Infections

Name

Location